Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT-01 in extensive-stage small cell lung cancer
NCT05205421Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of RT-01 in small cell lung cancer (SCLC), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoints: Incidence of adverse events at 6 months and Antitumor activity at 2 years. Status: unknown.
02
Drugs
RT-01
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05205421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205421.